ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Multiomics, pharmacogenomic, and structural characterization of NCCRP1 as a candidate therapeutic target in ovarian cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is characterized by extensive molecular heterogeneity and poor clinical outcomes, highlighting the need to identify biologically relevant therapeutic targets. NCCRP1 remains poorly characterized in ovarian cancer, and its molecular and therapeutic significance is largely unknown. In this study, we applied an integrative multiomics framework incorporating transcriptomic profiling, survival analysis, immune microenvironment characterization, pathway and network analyses, pharmacogenomic assessment, structural modeling, and single-cell RNA sequencing to investigate the role of NCCRP1 in ovarian cancer. Family-wide screening of the TCGA-OV cohort identified NCCRP1 as the only member significantly associated with overall survival. Elevated NCCRP1 expression was enriched in tumor tissues and associated with adverse clinical outcomes. Functional analyses demonstrated that NCCRP1-high tumors exhibit activation of epithelial-mesenchymal transition, cytoskeletal remodeling, adhesion signaling, and hypoxia-associated pathways, suggesting involvement in tumor plasticity and progression. Network-based analyses further positioned NCCRP1 within regulatory programs linked to structural reorganization and aggressive tumor phenotypes. Single-cell RNA sequencing confirmed that NCCRP1 expression is predominantly localized to malignant epithelial populations, supporting a tumor-intrinsic role. Pharmacogenomic analyses identified NCCRP1-associated transcriptional states linked to distinct drug sensitivity patterns, while structural modeling suggested the presence of a surface-accessible cavity capable of accommodating small molecules. Although these findings require experimental validation, they provide preliminary evidence supporting the potential druggability of NCCRP1. Our findings provide a comprehensive molecular characterization of NCCRP1 and support its prioritization as a candidate therapeutic target in ovarian cancer. This study demonstrates the utility of integrating multiomics, pharmacogenomic, structural, and single-cell approaches for therapeutic target discovery and prioritization in cancer.
Indexed as
Identifiers
42678551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.